Literature DB >> 14657533

Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program.

Lynn A Gloeckler Ries1, Marsha E Reichman, Denise Riedel Lewis, Benjamin F Hankey, Brenda K Edwards.   

Abstract

An overview of data on cancer at all sites combined and on selected, frequently occurring cancers is presented. Descriptive cancer statistics include average annual Surveillance, Epidemiology, and End Results (SEER) Program incidence, U.S. mortality and median age at diagnosis, and death for the period 1996-2000. Changes during the time period 1992-2000 are summarized by the annual percent change in SEER incidence and U.S. mortality data for this period. Five-year relative survival for selected cancers is examined by stage at diagnosis, based on data from 1990-1999. In addition, 5-year conditional survival for patients already surviving for 1-3 years after diagnosis is discussed as well as relative survival for other time periods. These measures may be more meaningful for clinical management and prognosis than 5-year relative survival from time of diagnosis. The likelihood of developing cancer during one's lifetime is 1 in 2 for males and 1 in 3 for females, based on 1998-2000 data. It is estimated that approximately 9.6 million people in the U.S. who have had a diagnosis of cancer are alive. Five-year relative survival varies greatly by cancer site and stage at diagnosis, and tends to increase with time since diagnosis. The median age at cancer diagnosis is 68 for men and 65 for women. The 5-year relative survival rate for persons diagnosed with cancer is 62.7%, with variation by cancer site and stage at diagnosis. For patients diagnosed with cancers of the prostate, female breast, corpus uteri, and urinary bladder, the relative survival rate at 8 years is over 75%.

Entities:  

Mesh:

Year:  2003        PMID: 14657533     DOI: 10.1634/theoncologist.8-6-541

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  109 in total

1.  Conditional survival among cancer patients in the United States.

Authors:  Ray M Merrill; Bradley D Hunter
Journal:  Oncologist       Date:  2010-07-20

2.  Developing a utility decision framework to evaluate predictive models in breast cancer risk estimation.

Authors:  Yirong Wu; Craig K Abbey; Xianqiao Chen; Jie Liu; David C Page; Oguzhan Alagoz; Peggy Peissig; Adedayo A Onitilo; Elizabeth S Burnside
Journal:  J Med Imaging (Bellingham)       Date:  2015-08-17

3.  Longitudinal perceptions of the side effects of chemotherapy in patients with gynecological cancer.

Authors:  Hui-Chun Hsu; Su-Yu Tsai; Shang-Liang Wu; Shiow-Roug Jeang; Mei-Yao Ho; Wen-Shiung Liou; An-Jen Chiang; Tsung-Hsien Chang
Journal:  Support Care Cancer       Date:  2017-06-21       Impact factor: 3.603

Review 4.  Informed consent in radiation oncology: is consenting easier than informing?

Authors:  Carmen González San Segundo; Juan A Santos Miranda
Journal:  Clin Transl Oncol       Date:  2006-11       Impact factor: 3.405

5.  Cancer patient survival improvement is correlated with the opening of a community cancer center: comparisons with intramural and extramural benchmarks.

Authors:  Robert O Dillman; Sherri D Chico
Journal:  J Oncol Pract       Date:  2005-09       Impact factor: 3.840

Review 6.  The viral etiology of AIDS-associated malignancies.

Authors:  Peter C Angeletti; Luwen Zhang; Charles Wood
Journal:  Adv Pharmacol       Date:  2008

Review 7.  Preventing neurocognitive late effects in childhood cancer survivors.

Authors:  Martha A Askins; Bartlett D Moore
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans.

Authors:  M Mazen Jamal; Eugene J Yoon; Kenneth J Vega; Mehrtash Hashemzadeh; Kenneth J Chang
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

9.  Are there biologic differences between male and female breast cancer explaining inferior outcome of men despite equal stage and treatment?!

Authors:  A-C Müller; C Gani; H M E Rehm; F Eckert; M Bamberg; T Hehr; M Weinmann
Journal:  Strahlenther Onkol       Date:  2012-08-01       Impact factor: 3.621

10.  Atherosclerosis and vascular aging as modifiers of tumor progression, angiogenesis, and responsiveness to therapy.

Authors:  Halka Klement; Brad St Croix; Chloe Milsom; Linda May; Qing Guo; Joanne L Yu; Petr Klement; Janusz Rak
Journal:  Am J Pathol       Date:  2007-09-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.